Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01MML
|
|||
| Former ID |
DNCL002314
|
|||
| Drug Name |
MLN9708
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Amyloidosis [ICD-11: 5D00] | Approved | [1], [2] | |
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Approved | [1], [2] | ||
| Company |
Millennium Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C20H23BCl2N2O9
|
|||
| Canonical SMILES |
B1(OC(=O)CC(O1)(CC(=O)O)C(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl
|
|||
| InChI |
1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-17(29)8-20(34-21,19(31)32)7-16(27)28)25-15(26)9-24-18(30)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,30)(H,25,26)(H,27,28)(H,31,32)/t14-,20?/m0/s1
|
|||
| InChIKey |
YTXSYWAKVMZICI-PVCZSOGJSA-N
|
|||
| CAS Number |
CAS 1201902-80-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
57291607, 85029113, 104253504, 124757626, 124955652, 125164430, 135268985, 135626848, 136340279, 136348738, 136367593, 138100925, 144116241, 152134539, 162011779, 162037798, 162202726, 162773434, 163326535, 163347633, 163908014, 164193936, 164834143, 174007116, 174526063, 177748936, 184814067, 198939582, 203355961, 210274689, 210280323, 223389604, 229732516, 248181513, 249810660, 252110098, 252166660, 252213184, 252443130
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proteasome (PS) | Target Info | Modulator | [3], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8450). | |||
| REF 2 | ClinicalTrials.gov (NCT02181413) A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant. U.S. National Institutes of Health. | |||
| REF 3 | Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010 Mar 1;70(5):1970-80. | |||
| REF 4 | Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.Blood.2012 Nov 8;120(19):3958-67. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.